We think the market is wrong about Opko Health (OPK). It’s acquisitions have already delivered profits and operating capital, buying it now could be an excellent long-term play. We are also looking to add this company to our EBIS list in the not too distant future.

Opko’s strategy of consolidating its recent acquisitions resulted in strong fourth-quarter earnings. It also made several advances in its products from collaborations with other companies. 

This stock is in a stealth bull market. Buy up to $11. Stop loss of $9.